Pre-vaccine era
Francis Home, a Scottish physician, demonstrated in 1757 that measles is caused by an infectious agent in the blood of patients.
In 1912, measles became a nationally notifiable disease in the United States, requiring U.S. healthcare providers and laboratories to report all diagnosed cases. In the first decade of reporting, an average of 6,000 measles-related deaths were reported each year.
A vaccine became available in 1963. In the decade before, nearly all children got measles by the time they were 15 years old. It is estimated 3 to 4 million people in the United States were infected each year. Among reported measles cases each year, an estimated:
- 400 to 500 people died
- 48,000 were hospitalized
- 1,000 suffered encephalitis (swelling of the brain)
Vaccine development
In 1954, John F. Enders and Dr. Thomas C. Peebles collected blood samples from several ill students during a measles outbreak in Boston, Massachusetts. They wanted to isolate the measles virus in the student’s blood and create a measles vaccine. They succeeded in isolating measles in 13-year-old David Edmonston’s blood.
In 1963, John Enders and colleagues transformed their Edmonston-B strain of measles virus into a vaccine and licensed it in the United States. In 1968, an improved measles vaccine, developed by Maurice Hilleman and colleagues, began to be distributed. This vaccine, called the Edmonston-Enders (formerly “Moraten”) strain has been the only measles vaccine used in the United States since 1968.
Measles vaccine is usually combined with mumps and rubella (MMR) vaccines, or combined with mumps, rubella and varicella (MMRV) vaccines.
Measles elimination in the United States
In 1978, CDC set a goal to eliminate measles from the United States by 1982. Although this goal was not met, widespread use of measles vaccine drastically reduced the disease rates. By 1981, the number of reported measles cases was 80% less compared with the previous year.
However, a 1989 measles outbreak among vaccinated school-aged children prompted the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) to recommend a second dose of MMR vaccine for all children. Following widespread implementation of this recommendation and improvements in first-dose MMR vaccine coverage, reported measles cases declined even more.
Historic achievement
Measles was declared eliminated from the United States in 2000. This meant the absence of the continuous spread of disease was greater than 12 months. This was thanks to a highly effective vaccination program in the United States, as well as better measles control in the Americas region.
Current status
Global measles cases increased in 2025 and 2026. This raises the risk for additional cases and spread in the United States, especially in communities with lower MMR vaccination coverage. MMR vaccination rates have decreased nationally, leaving some communities more vulnerable to measles introductions and rapid spread. Continuous measles spread (lasting at least 12 months) in the United States led to the loss of measles elimination status in 2026. CDC works with state and local jurisdictions and communities across the country to strengthen preparedness, support response efforts, and prevent further spread.